[{"id":"2482352c-3f42-43f1-a0f9-da11b351d807","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369312","created_at":"2022-05-11T16:55:51.065Z","updated_at":"2024-07-02T16:36:08.596Z","phase":"Phase 1","brief_title":"Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients","source_id_and_acronym":"NCT05369312","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-442096"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2022-06-20"}]